Exabis Library
Welcome to the e-CCO Library!
P481: Serum levels of infliximab associate with early mucosal healing in Crohn's disease: different “therapeutic window” between post-induction and maintenance treatment
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P481: Visceral fat to skeletal muscle area ratio predicts for Ustekinumab loss of response.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P482 Patient and physician perspectives on the management of inflammatory bowel disease: Disease remission and durability of treatment
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P482: Different characteristics of inflammatory bowel disease patients between tertiary referral centres and secondary hospitals
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P482: Early anti-TNF/immunomodulator therapy is associated with better clinical outcomes in Asian patients with Crohn's disease with poor prognostic factors
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P482: Pre-screening IBD patients starting biologic therapies, a positive single centre quality improvement project
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P482: Safety and efficacy of ustekinumab for Crohn’s disease in the elderly population
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P482: Selective prophylactic anti-tuberculosis strategy is superior for Chinese patients with inflammatory bowel disease receiving infliximab treatment: a multi-centre retrospective study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P482: The experiences of people with IBD and comorbid anxiety or depression and their views on an online intervention for people with long term conditions (COMPASS): A qualitative framework analysis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P482: Transanal minimally invasive proctectomy (TaMIP) in patients with inflammatory bowel diseases (IBD) within the TaTME international database
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P483 Vedolizumab serum drug levels are not associated with clinical outcomes or markers of disease activity in inflammatory bowel disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P483: Differences in biologic therapy utilisation amongst early and late-onset inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P483: Factors affecting the efficacy of granulomonocytapheresis in moderately-to-severely active ulcerative colitis: A multi-centre retrospective study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P483: Golimumab response in Ulcerative Colitis as early as week 2: What can we take from this?
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P483: Infliximab but not adalimumab drug levels predict faecal calprotectin response in Inflammatory Bowel Disease patients on dose-intensified anti-TNF therapy
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P483: Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: Explorative subgroup analyses in IBD from the NOR-SWITCH EXTENSION trial
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P483: Patient-reported quality of life, anxiety, and depression associated with switching originator infliximab to biosimilar
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P483: Relapse after discontinuation of the maintenance drug in patients with Ulcerative proctosigmoiditis: preliminary result of a prospective randomized trial
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P484 Effectiveness and safety of ustekinumab in patients with Crohn’s disease: a real-world experience
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P484: Access to biologics and biosimilars across 11 European Union countries
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM